Discovery of a broad-spectrum antiviral compound that inhibits pyrimidine biosynthesis and establishes a type 1 interferon-independent antiviral state

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 8, 2016, Pages 4552-4562

  Chung, Dong Hoon ^a,b   Golden, Jennifer E ^c,f   Adcock, Robert S ^b   Schroeder, Chad E ^c   Chu, Yong Kyu ^b   Sotsky, Julie B ^b   Cramer, Daniel E ^b   Chilton, Paula M ^a,g   Song, Chisu ^d   Anantpadma, Manu ^e   Davey, Robert A ^e   Prodhan, Aminul I ^b   Yin, Xinmin ^b   Zhang, Xiang ^b  

^a University of Louisville School of Medicine   (United States)

^b UNIVERSITY OF LOUISVILLE   (United States)

^c UNIVERSITY OF KANSAS   (United States)

^d NORTHWESTERN UNIVERSITY   (United States)

^e SOUTHWEST FOUNDATION FOR BIOMEDICAL RESEARCH   (United States)

^f UNIVERSITY OF WISCONSIN MADISON   (United States)

^g CHRISTINE M KLEINERT INSTITUTE FOR HAND AND MICROSURGERY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2 INTERFERON; ANTIVIRUS AGENT; BETA INTERFERON; INTERFERON; INTERFERON REGULATORY FACTOR 7; MYELOID DIFFERENTIATION FACTOR 88; OAS1 PROTEIN; OAS2 PROTEIN; PYRIMIDINE; RETINOIC ACID INDUCIBLE PROTEIN I; RNA 18S; TETRAHYDROBENZOTHIAZOLE; UNCLASSIFIED DRUG; PYRIMIDINE DERIVATIVE;

ALPHAVIRUS; ANIMAL CELL; ANTIVIRAL ACTIVITY; ARTICLE; BHK CELL LINE; CYTOPATHOGENIC EFFECT; EBOLAVIRUS; FEMALE; HEK293 CELL LINE; HELA CELL LINE; HERPES SIMPLEX VIRUS 2; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; INFLUENZA VIRUS; JAPANESE ENCEPHALITIS VIRUS; METABOLOMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PYRIMIDINE SYNTHESIS; ROUS SARCOMA VIRUS; VENEZUELAN EQUINE ENCEPHALITIS VIRUS; VIRUS REPLICATION; WEST NILE VIRUS; WESTERN EQUINE ENCEPHALITIS VIRUS; YELLOW FEVER VIRUS; BIOSYNTHESIS; CELL LINE; DRUG EFFECTS; METABOLISM; REAL TIME POLYMERASE CHAIN REACTION;

ANTIVIRAL AGENTS; CELL LINE; HIV-1; HUMANS; INTERFERON TYPE I; PYRIMIDINES; REAL-TIME POLYMERASE CHAIN REACTION; VIRUS REPLICATION;

EID: 84979582494     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00282-16     Document Type: Article

References (31)

1. Stedman C. 2014. Sofosbuvir, a NS5B polymerase inhibitor in the treatment of hepatitis C: a review of its clinical potential. Therap Adv Gastroenterol 7:131-140. http://dx.doi.org/10.1177/1756283X13515825.
2. Zeng QL, Zhang JY, Zhang Z, Wang LF, Wang FS. 2013. Sofosbuvir and ABT-450: terminator of hepatitis C virus? World J Gastroenterol 19:3199-3206.
3. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. 1972. Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 177:705-706. http://dx.doi.org/10.1126/science.177.4050.705.
4. Kumar R, Tripathi P, Baranwal M, Singh S, Tripathi S, Banerjee G. 2009. Randomized, controlled trial of oral ribavirin for Japanese encephalitis in children in Uttar Pradesh, India. Clin Infect Dis 48:400-406. http://dx.doi.org/10.1086/596309.
5. Mertz GJ, Miedzinski L, Goade D, Pavia AT, Hjelle B, Hansbarger CO, Levy H, Koster FT, Baum K, Lindemulder A, Wang W, Riser L, Fernandez H, Whitley RJ, Collaborative Antiviral Study Group. 2004. Placebo-controlled, double-blind trial of intravenous ribavirin for the treatment of hantavirus cardiopulmonary syndrome in North America. Clin Infect Dis 39:1307-1313.
6. Briolant S, Garin D, Scaramozzino N, Jouan A, Crance JM. 2004. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by antiviral compounds: synergistic effect of interferon-alpha and ribavirin combination. Antiviral Res 61:111-117. http://dx.doi.org/10.1016/j.antiviral.2003.09.005.
7. Mendenhall M, Russell A, Juelich T, Messina EL, Smee DF, Freiberg AN, Holbrook MR, Furuta Y, de la Torre JC, Nunberg JH, Gowen BB. 2011. T-705 (favipiravir) inhibition of arenavirus replication in cell culture. Antimicrob Agents Chemother 55:782-787. http://dx.doi.org/10.1128/AAC.01219-10.
8. Chung DH, Jonsson CB, Tower NA, Chu YK, Sahin E, Golden JE, Noah JW, Schroeder CE, Sotsky JB, Sosa MI, Cramer DE, McKellip SN, Rasmussen L, White EL, Schmaljohn CS, Julander JG, Smith JM, Filone CM, Connor JH, Sakurai Y, Davey RA. 2014. Discovery of a novel compound with anti-Venezuelan equine encephalitis virus activity that targets the nonstructural protein 2. PLoS Pathog 10:e1004213. http://dx.doi.org/10.1371/journal.ppat.1004213.
9. Schroeder CE, Yao T, Sotsky J, Smith RA, Roy S, Chu YK, Guo H, Tower NA, Noah JW, McKellip S, Sosa M, Rasmussen L, Smith LH, White EL, Aube J, Jonsson CB, Chung D, Golden JE. 2014. Development of (E)-2-((1,4-dimethylpiperazin-2-ylidene)amino)-5-nitro-N-phenylbenzamide, ML336: novel 2-amidinophenylbenzamides as potent inhibitors of Venezuelan equine encephalitis virus. J Med Chem 57:8608-8621. http://dx.doi.org/10.1021/jm501203v.
10. Bernard KA, Klimstra WB, Johnston RE. 2000. Mutations in the E2 glycoprotein of Venezuelan equine encephalitis virus confer heparan sulfate interaction, low morbidity, and rapid clearance from blood of mice. Virology 276:93-103. http://dx.doi.org/10.1006/viro.2000.0546.
11. Durocher Y, Perret S, Kamen A. 2002. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res 30:E9. http://dx.doi.org/10.1093/nar/30.2.e9.
12. Towner JS, Paragas J, Dover JE, Gupta M, Goldsmith CS, Huggins JW, Nichol ST. 2005. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology 332:20-27. http://dx.doi.org/10.1016/j.virol.2004.10.048.
13. Leung DW, Borek D, Luthra P, Binning JM, Anantpadma M, Liu G, Harvey IB, Su Z, Endlich-Frazier A, Pan J, Shabman RS, Chiu W, Davey RA, Otwinowski Z, Basler CF, Amarasinghe GK. 2015. An intrinsically disordered peptide from Ebola virus VP35 controls viral RNA synthesis by modulating nucleoprotein-RNA interactions. Cell Rep 11:376-389. http://dx.doi.org/10.1016/j.celrep.2015.03.034.
14. Wei X, Shi X, Koo I, Kim S, Schmidt RH, Arteel GE, Watson WH, McClain C, Zhang X. 2013. MetPP: a computational platform for comprehensive two-dimensional gas chromatography time-of-flight mass spectrometry-based metabolomics. Bioinformatics 29:1786-1792. http://dx.doi.org/10.1093/bioinformatics/btt275.
15. Lucas-Hourani M, Dauzonne D, Jorda P, Cousin G, Lupan A, Helynck O, Caignard G, Janvier G, Andre-Leroux G, Khiar S, Escriou N, Despres P, Jacob Y, Munier-Lehmann H, Tangy F, Vidalain PO. 2013. Inhibition of pyrimidine biosynthesis pathway suppresses viral growth through innate immunity. PLoS Pathog 9:e1003678. http://dx.doi.org/10.1371/journal.ppat.1003678.
16. Diaz MO, Ziemin S, Le Beau MM, Pitha P, Smith SD, Chilcote RR, Rowley JD. 1988. Homozygous deletion of the alpha- and beta 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci USA85:5259-5263. http://dx.doi.org/10.1073/pnas.85.14.5259.
17. Hoffmann HH, Kunz A, Simon VA, Palese P, Shaw ML. 2011. Broad-spectrum antiviral that interferes with de novo pyrimidine biosynthesis. Proc Natl Acad Sci U S A 108:5777-5782. http://dx.doi.org/10.1073/pnas.1101143108.
18. Wang QY, Bushell S, Qing M, Xu HY, Bonavia A, Nunes S, Zhou J, Poh MK, Florez de Sessions P, Niyomrattanakit P, Dong H, Hoffmaster K, Goh A, Nilar S, Schul W, Jones S, Kramer L, Compton T, Shi PY. 2011. Inhibition of dengue virus through suppression of host pyrimidine biosynthesis. J Virol 85:6548-6556. http://dx.doi.org/10.1128/JVI.02510-10.
19. Smee DF, Hurst BL, Day CW. 2012. D282, a non-nucleoside inhibitor of influenza virus infection that interferes with de novo pyrimidine biosynthesis. Antivir Chem Chemother 22:263-272. http://dx.doi.org/10.3851/IMP2105.
20. Yablonski MJ, Pasek DA, Han BD, Jones ME, Traut TW. 1996. Intrinsic activity and stability of bifunctional human UMP synthase and its two separate catalytic domains, orotate phosphoribosyltransferase and orotidine-5′-phosphate decarboxylase. J Biol Chem 271:10704-10708. http://dx.doi.org/10.1074/jbc.271.18.10704.
21. Kuo RL, Kao LT, Lin SJ, Wang RY, Shih SR. 2013. MDA5 plays a crucial role in enterovirus 71 RNA-mediated IRF3 activation. PLoS One 8(5): e63431. http://dx.doi.org/10.1371/journal.pone.0063431.
22. Rasmussen SB, Jensen SB, Nielsen C, Quartin E, Kato H, Chen ZJ, Silverman RH, Akira S, Paludan SR. 2009. Herpes simplex virus infection is sensed by both Toll-like receptors and retinoic acid-inducible gene-like receptors, which synergize to induce type I interferon production. J Gen Virol 90:74-78. http://dx.doi.org/10.1099/vir.0.005389-0.
23. Qing M, Zou G, Wang QY, Xu HY, Dong H, Yuan Z, Shi PY. 2010. Characterization of dengue virus resistance to brequinar in cell culture. Antimicrob Agents Chemother 54:3686-3695. http://dx.doi.org/10.1128/AAC.00561-10.
24. Yeo KL, Chen YL, Xu HY, Dong H, Wang QY, Yokokawa F, Shi PY. 2015. Synergistic suppression of dengue virus replication using a combination of nucleoside analogs and nucleoside synthesis inhibitors. Antimicrob Agents Chemother 59:2086-2093. http://dx.doi.org/10.1128/AAC.04779-14.
25. Zhu JZ, Zhang YG, Ghosh A, Cuevas RA, Forero A, Dhar J, Ibsen MS, Schmid-Burgk JL, Schmidt T, Ganapathiraju MK, Fujita T, Hartmann R, Barik S, Hornung V, Coyne CB, Sarkar SN. 2014. Antiviral activity of human OASL protein is mediated by enhancing signaling of the RIG-I RNA sensor. Immunity 40:936-948. http://dx.doi.org/10.1016/j.immuni.2014.05.007.
26. Chung D. 2016. The establishment of an antiviral state by pyrimidine synthesis inhibitor is cell type-specific. J Antimicrob Agents 1:101.
27. Grandin C, Hourani ML, Janin YL, Dauzonne D, Munier-Lehmann H, Paturet A, Taborik F, Vabret A, Contamin H, Tangy F, Vidalain PO. 2016. Respiratory syncytial virus infection in macaques is not suppressed by intranasal sprays of pyrimidine biosynthesis inhibitors. Antiviral Res 125:58-62. http://dx.doi.org/10.1016/j.antiviral.2015.11.006.
28. Bonavia A, Franti M, Pusateri Keaney E, Kuhen K, Seepersaud M, Radetich B, Shao J, Honda A, Dewhurst J, Balabanis K, Monroe J, Wolff K, Osborne C, Lanieri L, Hoffmaster K, Amin J, Markovits J, Broome M, Skuba E, Cornella-Taracido I, Joberty G, Bouwmeester T, Hamann L, Tallarico JA, Tommasi R, Compton T, Bushell SM. 2011. Identification of broad-spectrum antiviral compounds and assessment of the drug-gability of their target for efficacy against respiratory syncytial virus (RSV). Proc Natl Acad Sci U S A 108:6739-6744. http://dx.doi.org/10.1073/pnas.1017142108.
29. Josephson MA, Javaid B, Kadambi PV, Meehan SM, Williams JW. 2006. Leflunomide in solid organ transplantation and polyoma virus infection. Adv Exp Med Biol 577:255-265. http://dx.doi.org/10.1007/0-387-32957-9-18.
30. Dunn MC, Knight DA, Waldman WJ. 2011. Inhibition of respiratory syncytial virus in vitro and in vivo by the immunosuppressive agent leflunomide. Antivir Ther 16:309-317. http://dx.doi.org/10.3851/IMP1763.
31. Jung YH, Moon KC, Ha JW, Kim SJ, Ha IS, Cheong HI, Kang HG. 2013. Leflunomide therapy for BK virus allograft nephropathy after pediatric kidney transplantation. Pediatr Transplant 17:E50-E54. http://dx.doi.org/10.1111/petr.12029.